BSIM Therapeutics is awarded a US Patent

13 August, 2019

Large uspto seal

BSIM Therapeutics has been awarded a United States Patent (Patent #10,377,729) for one of its promising technologies in the stabilization of transthyretin (TTR) and with potential application in the treatment of TTR-mediated amyloidosis (ATTR).

With this and other technologies under development, BSIM therapeutics expects to raise to the challenge of answering to the unmet medical needs affecting patients with life-threatening TTR amyloidosis.

By continuing to browse the site, you expressly agree that cookies will be stored on your computer to help measure statistics of visits and improve the quality of the contents offered.Learn more